News & Resources

Overview

Webcast ImageWebcast
Orexigen Therapeutics, Inc. at 35th Annual J.P. Morgan Healthcare Conference  (Replay)
01/12/17 at 10:00 a.m. PT
Orexigen Therapeutics, Inc. at 35th Annual J.P. Morgan Healthcare Conference
Thursday, January 12, 2017 10:00 a.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolonged relMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.21
Change (%)0.00 (0.00%)
Volume308,400
Jan 20, 2017 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
DateTitle 
01/06/17Orexigen Therapeutics Announces Publication of Contrave® (naltrexone HCl and bupropion HCl extended-release tablets) Real-World Study Results in "Obesity"Printer Friendly Version
01/05/17Orexigen Therapeutics Highlights Key Business Priorities for 2017Printer Friendly Version
01/03/17Orexigen Therapeutics Launches "Brains Behind Weight Loss," a Dynamic Patient Focused Campaign to Educate Consumers on the Role of the Brain in Weight LossPrinter Friendly Version
12/19/16Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Biologix FZCO for Contrave® (naltrexone HCl / bupropion HCl prolonged release) for Ten Countries in the Middle EastPrinter Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.